The government is apparently conducting a study on the cost-effectiveness of expanding the human papillomavirus (HPV) vaccination subject and vaccine types. The outcome of the research could affect the pharmaceutical industry.

On Feb. 24, the Korea Disease Control and Prevention Agency (KDCA) official answered Democratic Party Lawmaker Choi Hye-young asking about the agency’s clear stance on the expansion of HPV vaccination subject, as a part of the low birthrate and aging society responding master plan, and said a relevant research is ongoing at the moment.

KDCA official elaborated, “The Fourth Low Birthrate and Aging Society Responding Master Plan states the government would review